NFE2L2 rs672137: What Your Genotype Means
The rs672137 variant is a single-nucleotide polymorphism located in the promoter region of the NFE2L2 gene, which encodes the master antioxidant transcription factor NRF2. Research indicates that this variant can modulate the transcriptional activity of NRF2, influencing cellular defense against oxidative stress. Genome-wide association and candidate-gene studies have evaluated its link to cardiovascular health and oxidative phenotypes, though overall clinical evidence remains limited.
What each genotype means
Typical antioxidant response activity
You carry two copies of the common C allele in the promoter region of the NFE2L2 gene. Published functional studies indicate that this genotype displays standard baseline promoter activity and typical cellular antioxidant pathway induction. Research associations between this genotype and oxidative stress-related cardiovascular outcomes are generally neutral.
Carried by approximately 55% to 65% of people globally, being most frequent in individuals of European and African ancestries.
Moderately altered antioxidant activity
You carry one copy of the C allele and one copy of the G allele. In laboratory models, the G allele has been associated with altered promoter binding and slightly reduced transcriptional induction of NRF2 target genes. While some association studies observe modest statistical links to cardiovascular risk markers, clinical evidence remains limited and findings vary across ancestries.
Carried by roughly 30% to 35% of people worldwide, occurring at higher frequencies in East Asian populations.
Reduced antioxidant response transcription
You carry two copies of the G allele in the NFE2L2 promoter region. Research suggests this genotype leads to reduced basal and stress-induced transcription of NRF2, which regulates cellular defense against oxidative stress. Clinical associations with cardiovascular risk and oxidative phenotypes have been reported, although overall evidence remains limited and is not diagnostic of any health condition.
Carried by roughly 3% to 6% of individuals of European and African descent, and up to 8% to 10% of individuals of East Asian descent.
Molecular Anatomy of rs672137
The single-nucleotide polymorphism rs672137 is situated within the regulatory promoter region of the NFE2L2 gene on chromosome 2. In historical literature, it is frequently described as the -617C/A or -653C/G promoter polymorphism depending on the reference sequence and strand notation used. According to standard genomic coordinates in dbSNP, the alleles are commonly referenced as T and G (or C and A on the opposite strand). Because it is positioned in an upstream promoter site, it does not alter the amino acid sequence of the final protein. Instead, functional studies indicate that changes at this locus can influence transcription factor binding affinity. This altered binding capacity directly affects baseline promoter activity, causing differences in how effectively the cell initiates transcription of the NFE2L2 gene when challenged by metabolic byproducts or environmental oxidants.
The Biological Role of NFE2L2 and NRF2
The NFE2L2 gene encodes Nuclear Factor Erythroid 2-Related Factor 2, universally known as NRF2. NRF2 operates as the primary transcriptional regulator of cellular antioxidant defense and phase II detoxification pathways. Under physiological conditions, NRF2 is kept at low levels in the cytoplasm by its inhibitor protein KEAP1, which marks it for rapid proteasomal degradation. When cellular stress or electrophilic compounds emerge, KEAP1 is modified, releasing NRF2 so it can translocate into the cell nucleus. Once inside the nucleus, NRF2 heterodimerizes and binds to antioxidant response elements (AREs) located in the promoters of hundreds of protective genes, including enzymes that synthesize glutathione and neutralize reactive oxygen species. Because NRF2 serves as a central switch for redox homeostasis, subtle genetic changes affecting its expression can reverberate through many downstream metabolic pathways.
Associated Traits and Scientific Evidence
Epidemiological studies and genome-wide association surveys have probed rs672137 for potential connections to diverse human phenotypes, predominantly cardiovascular disease risk, endothelial function, respiratory decline, and markers of systemic oxidative stress. Certain candidate-gene studies suggest that individuals carrying the minor allele display diminished NFE2L2 promoter activity, leading to lower induction of antioxidant enzymes when exposed to vascular stressors like smoking or elevated lipids. However, the overall strength of this evidence is cataloged as limited. Findings across cohorts are mixed, with effect sizes generally modest and often failing to reach stringent genome-wide statistical significance in broader unselected populations. Environmental variables, diet, and lifestyle habits strongly interact with NRF2 pathway signaling, which complicates attempts to isolate rs672137 as an independent diagnostic or prognostic factor.
Interpreting Results and Actionable Boundaries
Learning your rs672137 genotype provides educational insight into one component of your cellular antioxidant response network, but it cannot be used to diagnose, predict, or treat any medical condition. A variant that subtly alters promoter activity does not determine your cardiovascular or metabolic future; human health is governed by vast networks of interacting genes alongside critical lifestyle factors. Genotype reports should never be used as a reason to alter prescribed therapy or initiate high-dose antioxidant supplements, which can sometimes produce paradoxical biological effects. Readers who have concerns about cardiovascular markers, metabolic health, or oxidative stress should focus on clinically established pillars like regular physical exercise and balanced nutrition, discussing any testing or medication concerns directly with a qualified healthcare professional.
How common is this variant?
The minor allele frequency for rs672137 is approximately 18% to 25% across global populations, reaching its highest frequencies in East Asian ancestral groups and lower frequencies in European and African ancestries.
Frequently asked questions
What is the NFE2L2 rs672137 genetic variant?
The rs672137 variant is a single-nucleotide polymorphism located in the promoter region of the NFE2L2 gene. It acts as a regulatory variant that can influence how efficiently the gene is transcribed into the NRF2 antioxidant defense protein.
Does having the minor allele mean I have high oxidative stress?
No, carrying the minor allele does not mean you have clinically elevated oxidative stress or cellular damage. Cellular redox balance depends on dozens of overlapping antioxidant systems, diet, sleep, and physical activity rather than any single genetic variant.
Can rs672137 diagnose cardiovascular disease?
No, rs672137 has no diagnostic power for heart disease or any other medical condition. The statistical associations identified in research studies reflect slight population-level tendencies and do not provide predictive clinical utility for individuals.
Should I take high-dose antioxidant supplements if I carry rs672137?
You should not start high-dose antioxidant supplements based on this genotype, as excessive supplementation can interfere with normal cellular signaling. Any decisions regarding targeted nutritional supplements or dietary changes should be evaluated with your doctor or a registered dietitian.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs672137?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29